Effectiveness of pharmacist dosing adjustment for critically ill patients receiving continuous renal replacement therapy: A comparative study

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 405-412

  Jiang, Sai Ping ^a   Zhu, Zheng Yi ^b   Wu, Xiao Liang ^a   Lu, Xiao Yang ^a   Zhang, Xing Guo ^a   Wu, Bao Hua ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adverse drug event; Cost saving; CRRT; Drug dosing adjustment; Pharmacist interventions

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTINUOUS RENAL REPLACEMENT THERAPY; COST CONTROL; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MORTALITY; OUTCOME ASSESSMENT; PHARMACIST ATTITUDE; RISK FACTOR;

EID: 84902000319     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S59187     Document Type: Article

References (24)

1. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32(3):362-375.
2. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166.
3. Prowle JR, Schneider A, Bellomo R. Clinical review: Optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care. 2011;15(2):207.
4. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45(8):929-934.
5. González de Molina FJ, Ferrer R. Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care. 2011;15(4):175.
6. Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 2010;30(3):195-212.
7. Seyler L, Cotton F, Taccone FS, etal. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137.
8. Churchwell MD, Mueller BA. Drug dosing during continuous renal replacement therapy. Semin Dial. 2009;22(2):185-188.
9. Thompson AJ. Drug dosing during continuous renal replacement therapies. J Pediatr Pharmacol Ther. 2008;13(2):99-113.
10. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137.
11. Glossop A, Seidel J. Dosing regimes for antimicrobials during continuous veno-venous haemofiltration (CVVH). J Intensive Care Soc. 2008;9(2):160-165.
12. Gavaza P, Brown CM, Lawson KA, Rascati KL, Steinhardt M, Wilson JP. Pharmacist reporting of serious adverse drug events to the Food and Drug Administration. J Am Pharm Assoc (2003). 2012;52(5): e109-e112.
13. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801.
14. Nebeker JR, Hurdle JF, Hoffman J, Roth B, Weir CR, Samore MH. Developing a taxonomy for research in adverse drug events: potholes and signposts. Proc AMIA Symp. 2001:493-497.
15. Park SK, Chun HJ, Kim DW, Im TH, Hong HJ, Yi HJ. Acute Physiology and Chronic Health Evaluation II and Simplified Acute Physiology Score II in predicting hospital mortality of neurosurgical intensive care unit patients. J Korean Med Sci. 2009;24(3):420-426.
16. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007;13(6):645-651.
17. Roberts DM, Roberts JA, Roberts MS, etal; RENAL Replacement Therapy Study Investigators. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012;40(5): 1523-1528.
18. Montazeri M, Cook DJ. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med. 1994;22(6): 1044-1048.
19. Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM. Analysis of risk factors for adverse drug events in critically ill patients*. Crit Care Med. 2012;40(3):823-828.
20. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163(17):2014-2018.
21. Mergenhagen KA, Blum SS, Kugler A, etal. Pharmacist-versus physician-initiated admission medication reconciliation: impact on adverse drug events. Am J Geriatr Pharmacother. 2012;10(4):242-250.
22. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23):2483-2487.
23. Klopotowska JE, Kuiper R, van Kan HJ, etal. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care. 2010;14(5):R174.
24. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5): 691-698.